Condition category
Mental and Behavioural Disorders
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
DIALOG+ is an intervention delivered on a tablet using an App. It is designed to help mental health professionals to improve the structure of their routine meetings with patients. It also helps to improve communication with patients during these meetings. Patients are first asked about how satisfied they are with eight areas of their life (e.g. physical health, family relationships, leisure activities) and three areas of the treatment they are receiving (e.g. practical help, meetings) which is called the DIALOG scale. The patient then chooses up to three areas to discuss in more depth with their health professional. The clinician then discusses each area chosen by the patient, using a four-step approach that focuses on solutions to the identified problems. This study aims to find out whether DIALOG+ can help to improve care for people living with severe mental illness in Peru. More specifically, the aim is to find out how patients and health professionals experience DIALOG+ when it is used during their routine meetings, and to find out if DIALOG+ improves outcomes like quality of life and symptoms.

Who can participate?
Patients aged 18-65 with a primary diagnosis of severe mental illness receiving care at one of the study sites

What does the study involve?
Patients use the App within their routine clinical appointments once per month for a period of 6 months. Patients and clinicians who have used DIALOG+ are also interviewed to see how they experienced the intervention.

What are the possible benefits and risks of participating?
Severe mental illnesses cause high levels of distress to affected individuals. In countries such as Peru there is often a lack of human and financial resources for specialised mental health services in the community. This study will provide evidence on how to include effective and long-lasting local-based interventions for community based mental health programs in the country. Overall, the study will build both mental health and research capacity within Peru. Additionally, for patients who will be involved in testing the intervention, this might lead to improved quality of life and symptom reduction. Mental health professionals will also benefit in terms of the training and supervision they will receive to enable them to implement the intervention. No significant risks are expected from participating in this study, but it is possible that whilst completing the research assessment or qualitative interviews, the questions asked might trigger feelings of distress or anxiety. To minimise this risk, researchers with experience working with people with severe mental illness were employed. Additionally, research assessments can be stopped at any point, and further support can be provided to the participant if necessary. Participants might also experience anxiety in trying new interventions. Through the intervention-testing period, individuals will continue to receive their routine care, including any medication. The intervention can be stopped at any point.

Where is the study run from?
1. Carabayllo CMHC (Peru)
2. San Gabriel Alto CMHC (Peru)
3. Honorio Delgado CMHC (Peru)
4. La Victoria CMHC (Peru)

When is the study starting and how long is it expected to run for?
July 2019 to March 2021 (updated 11/08/2020, previously :November 2020; updated 14/04/2020, previously: September 2020; updated 05/11/2019, previously: July 2020)

Who is funding the study?
National Institute for Health Research (UK)

Who is the main contact?
1. Ms Sana Sajun
2. Ms Catherine Fung
3. Ms Erin Burn

Trial website

Contact information



Primary contact

Ms Sana Sajun


Contact details

Unit for Social and Community Psychiatry
Newham Centre for Mental Health
E13 8SP
United Kingdom
+44 (0)20 540 4380 Ext: 2312



Additional contact

Ms Catherine Fung


Contact details

Unit for Social and Community Psychiatry
Newham Centre for Mental Health
E13 8SP
United Kingdom
+44 (0)20 540 4380 Ext: 2312



Additional contact

Ms Erin Burn


Contact details

Unit for Social and Community Psychiatry
Newham Centre for Mental Health
E13 8SP
United Kingdom
+44 (0)20 540 4380 Ext: 2344



Additional contact

Dr Francois van Loggerenberg


Contact details

Unit for Social and Community Psychiatry
Newham Centre for Mental Health
E13 8SP
United Kingdom
+44 (0)20 540 4380 Ext: 2312



Additional contact

Dr Michael McGrath


Contact details

Unit for Social and Community Psychiatry
Newham Centre for Mental Health
E13 8SP
United Kingdom
+44 (0)20 540 4380 Ext: 2312

Additional identifiers

EudraCT number

Nil known number

Nil known

Protocol/serial number


Study information

Scientific title

Testing the effectiveness, acceptability and feasibility of DIALOG+ in severe mental illness in Peru: a non-controlled trial


Study hypothesis

To test the acceptability, feasibility and effectiveness of DIALOG+.
The specific research questions are:
1. How can DIALOG+ be used to support community mental health care in Peru?
2. How is DIALOG+ experienced by patients and professionals?
3. How do patient outcomes change when DIALOG+ is used?

Ethics approval

1. Approved 10/06/2019, Universidad Peruana Cayetano Heredia Ethics Committee (Dra. Frine Samalvides Cuba, Av. Honorio Delgado 430, Lima, Peru; Tel: +511 319-0000 ext 201352; e-mail duict@oficinas-upch.per), ref:103031
2. Approved 03/06/2019, Queen Mary Ethics of Research Committee (Hazel Covill, Room W117, Finance Department, Queens' Building, Queen Mary University of London, Mile End Road, London, E1 4NS; Tel: +44 (0)20 7882 7915; Email:, ref: QMERC2019/43

Study design

Interventional single-centre non-controlled study

Primary study design


Secondary study design

Non randomised study

Trial setting


Trial type

Quality of life

Patient information sheet

Not available in web format, please use contact details to request a participant information sheet


Patients with severe mental illness (including psychosis, bipolar disorder and severe depression)


At least 5 clinicians, and 40 patients will be recruited. Patients will receive DIALOG+ at their routine clinical appointments once per month. This will be delivered by their usual clinician using an app on a tablet computer. The intervention will be over 6 months during which patients will receive 6-7 DIALOG+ sessions. DIALOG+ is a technology-mediated intervention, which involves a structured patient assessment covering satisfaction with eight life domains and three treatment domains (DIALOG scale) and a four-step solution-focused therapy approach to address patient concerns (DIALOG+). DIALOG+ aims to make routine meetings between clinicians and patients therapeutically effective.

Intervention type



Drug names

Primary outcome measure

Quality of life, measured using the Manchester Short Assessment of Quality of Life (MANSA) at baseline and 6 months

Secondary outcome measures

1. Objective social functioning, measured using the Objective Social Outcome Index (SIX) at baseline and 6 months
2. Symptoms, measured using the Brief Psychiatric Rating Scale (BPRS) at baseline and 6 months
3. Service use, measured using adapted Client Service Receipt Inventory (CSRI) at baseline and 6 months
4. Patients' experience of the DIALOG+ intervention assessed using qualitative interviews at 6 months

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Primary diagnosis of severe mental illness as defined by ICD10: F20-9, F31, F32
2. Aged 18-65 years old
3. Capacity to provide informed consent
4. Score of 5 or below on the MANSA scale
5. Receiving care from a participating health care provider

Participant type


Age group




Target number of participants

40 patients (5 healthcare providers)

Total final enrolment


Participant exclusion criteria

1. Diagnosis of dementia or organic psychosis as determined by their health providers
2. Primary diagnosis of substance use disorder
3. Severe learning difficulties or severe cognitive disability

Recruitment start date


Recruitment end date



Countries of recruitment


Trial participating centre

Carabayllo CMHC
Micaela Bastidas 433, Carabayllo

Trial participating centre

San Gabriel Alto CMHC
Leoncio Prado S/N, Villa María del Triunfo

Trial participating centre

Honorio Delgado CMHC
Eloy Espinoza, Urb 709, San Martín de Porres

Trial participating centre

La Victoria CMHC
Jr. Antonio Bazo S/N, La Victoria

Sponsor information


Queen Mary University of London

Sponsor details

Blizard Building
4 Newark St
E1 2AT
United Kingdom
+44 (0)20 7540 4380 ext: 2312

Sponsor type




Funder type


Funder name

National Institute for Health Research

Alternative name(s)


Funding Body Type

government organisation

Funding Body Subtype

National government


United Kingdom

Results and Publications

Publication and dissemination plan

The researchers intend to publish the quantitative and qualitative findings from this study by August 2020. Regarding dissemination, this study is part of a research group which also aims to build sustainable research capacity. The dissemination plan therefore aims to inform research, policy and practice. The researchers plan to disseminate findings across Peru. Dissemination will include publications, attending conferences, and using platforms like Twitter and the group website.

IPD sharing statement:
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. The datasets will be held at QMUL in anonymised form. Data sharing with external interests will be considered only after the publication of the findings that reflect the given data. The datasets will be available upon request from Stefan Priebe ( The data collected will be both quantitative and qualitative. The duration of availability of data has not yet been decided. During the course of the study, data will be shared internally between the research group using an online data collection platform called REDCap. The method for sharing the data externally (if required) will be decided in due course. Informed consent will be obtained from all participants involved in the study. All participants are assigned a patient ID at the point of enrolment and all subsequent data collected will be linked to this ID, without any link to identifiable data following Good Clinical Practice.

Intention to publish date


Participant level data

Available on request

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes

11/08/2020: The following changes have been made: 1. The overall trial end date has been changed from 31/07/2020 to 31/03/2021. 2. Two scientific contacts have been added. 2. The plain English summary has been updated to reflect the changes above. 14/04/2020: The overall trial end date has been changed from 30/09/2020 to 30/11/2020 and the plain English summary has been updated to reflect this. 12/02/2020: The total final enrolment number has been added. 20/11/2019: The following changes were made to the trial record: 1. The recruitment end date was changed from 31/01/2020 to 15/01/2020. 2. The intention to publish date was changed from 30/09/2021 to 31/07/2021. 05/11/2019: The following changes were made to the trial record: 1. The recruitment end date was changed from 31/10/2019 to 31/01/2020. 2. The overall end date was changed from 31/07/2020 to 30/09/2020. 3. The intention to publish date was changed from 31/07/2020 to 30/09/2021. 4. The plain English summary was updated to reflect these changes. 08/07/2019: Trial's existence confirmed by ethics committee. Uploaded protocol (not peer reviewed).